Polaris Pharmaceuticals, Inc
4941 Allison Parkway, Suite B
Vacaville
CA
95688
United States
Tel: 707-451-0441
Website: http://www.polarispharma.com/
Email: support@polarispharma.com
About Polaris Pharmaceuticals, Inc
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China
Stock Exchange: Taiwan
Stock Symbol: 6550.TDW
8 articles about Polaris Pharmaceuticals, Inc
-
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
12/22/2023
Polaris Group announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.
-
Polaris Group's Strategic Partner Nanotein Technologies Launches GROW-NK, a Revolutionary NK Cell Activation and Expansion Reagent, Propelling the Field of NK Cell Therapy
6/7/2023
Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today announced...
-
Polaris to Expand Vacaville Site with Acquisition of 15 Acres
1/26/2022
Polaris Pharmaceuticals, Inc. Vacaville has purchased 15 acres in the City of Vacaville’s Vaca Valley Business Park, a transaction that represents another advancement in the City’s plans to expand its biotechnology footprint and solidify itself as a global center for biomanufacturing.
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board
7/9/2018
Polaris Pharmaceuticals, Inc. announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board.
-
Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research
5/10/2018
Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy Platform, led by world-renowned immunotherapy pioneer Dr. James Allison, Dr. Padmanee Sharma, and Dr. Patrick Hwu, to design clinical studies and monitor biomarkers in immune functions associated with the therapies.
-
Polaris Pharmaceuticals Adopts Medidata Solutions, Inc. Payments
9/20/2016
-
Polaris Pharmaceuticals Release: ADI-PEG 20 Is A Potential Salvage Therapy For BRAFi Resistant Melanoma
4/19/2016